Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,025 public trials 2,027 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT04394650

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 103 Birmingham, Alabama, United States
  • Local Institution - 111 Phoenix, Arizona, United States
  • Local Institution - 110 Stanford, California, United States
  • Local Institution - 107 Chicago, Illinois, United States
View Trial Details
Completed

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT04434196

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Local Institution - 106 Boston, Massachusetts, United States
  • Local Institution - 104 Columbus, Ohio, United States
  • Local Institution - 101 Portland, Oregon, United States
  • Local Institution - 107 Dallas, Texas, United States
View all 15 locations
View Trial Details
Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

NCT02920697

Conditions
B-Cell Non-Hodgkin Lymphoma (NHL), Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services Melbourne, Australia
  • Hopital Claude Huriez Lille, France
  • CHU de Nantes Nantes, France
  • Centre hospitalier Lyon Sud Pierre-Bénite, France
View all 18 locations
View Trial Details
Completed

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cutaneous T Cell Lymphoma, +23 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Jacksonville, Florida, United States
  • Columbia University Medical Center New York, United States
  • University Hospitals Cleveland Seidman Cancer Center Cleveland, Ohio, United States
View all 18 locations
View Trial Details
Completed

A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

NCT04840680

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hallym University Sacred Heart Hospital Anyang, South Korea
  • SOONCHUNHYANG UNIVERSITY HOSPITAL Bucheon Bucheon-si, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Pusan National University Hospital Busan, South Korea
View all 20 locations
View Trial Details

Related conditions